Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Circadian system ageing in cancer: from tumourigenesis to treatment

Project description

How ageing impacts the circadian biology of cancer

Age is a leading risk factor for cancer. The decline of circadian rhythms with ageing may alter cancer biology and treatment responses. Important questions include whether ageing changes the impact of circadian disruption on tumours and how established tumour rhythms are affected by host ageing. The ERC-funded CircTu-Age project will combine advanced models of ageing and cancer with targeted disruptions of circadian rhythms. It will explore how ageing impacts the circadian biology of cancer and uncover the link between circadian rhythm decay (an emerging hallmark of ageing) and cancer, a prevalent age-related disease. The findings could help identify interventions to reduce cancer risk later in life and advance the field of cancer chronotherapy.

Objective

Age is cancer's primary risk factor and a significant determinant of how the resulting disease presents and
progresses. Yet the specific contribution of ageing’s diverse hallmarks to this phenomenon is poorly defined.
Circadian rhythms are a conserved adaptation that enables organisms to anticipate daily environmental
cycles and thus mitigate their harmful effects on the body. However, in recent years, a decay of homeostatic
cellular, tissue and systemic circadian rhythms has emerged as a hallmark of mammalian ageing.
Concurrently, in the context of cancer, circadian inputs from the host are known to drive daily rhythms in
tumour microenvironment composition, metastasis seeding and treatment response, whilst disruption of
physiological circadian rhythms is itself an established tumour promoter. When considered together, this
raises the intriguing possibility that ageing of the circadian system may reshape cancer circadian biology in a
manner pertinent to its prevention or treatment.

In particular, three key questions emerge: 1) Does ageing of the body and its circadian rhythm system change
the tumourigenic potency of circadian rhythm disruption? 2) Are the circadian rhythms of an established
tumour altered by ageing of the host and its circadian system? 3) If cancer circadian biology is rewired by
ageing, can we identify where this change originates from?

In CircTu-Age, we will combine cutting-edge models of ageing and cancer with targeted circadian rhythm
disruption and circadian-omics to define how ageing impinges upon the circadian biology of cancer. This
timely project will reveal the as-yet-uncharacterised interaction between an emerging hallmark of ageing,
circadian rhythm decay, and the most common of age-related diseases, cancer. The knowledge generated by
CircTu-Age will provide a roadmap for identifying interventions that diminish cancer risk later in life, and
contribute to refining and expanding the burgeoning field of cancer chronotherapy.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Net EU contribution
€ 1 499 300,00
Address
CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA
08028 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
€ 1 499 300,00

Beneficiaries (1)